α-(4-Δ³-Pyrrolidino-phenyl)-essigsaeure | 26576-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: α-(4-Δ³-Pyrrolidino-phenyl)-essigsaeure
• 英文别名: 4-(3-Pyrrolin-1-yl)-phenylessigsaeure；(4-Pyrrolinophenyl)-essigsaeure；2-[4-(2,5-Dihydropyrrol-1-yl)phenyl]acetic acid
• CAS: 26576-71-6
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.241
• InChiKey: HHAWCKJIQFQNDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-苯基-2,5-二氢-1H-吡咯 、 氯乙酸 、 三氯化铝 生成 α-(4-Δ³-Pyrrolidino-phenyl)-essigsaeure
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF
  申请人：JENKEM TECHNOLOGY CO. LTD. TIANJIN BRANCH

  公开号：US20150359900A1

  公开（公告）日：2015-12-17

  A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below and a pharmaceutical composition comprising the conjugate are provided. In the conjugate, P is a water soluble polymer; X is a linking group, wherein the linking group links P and A 1 ; each of A 1 , A 2 and A 3 is independently same or different amino acid residue or amino acid analogue residue; each of D 1 and D 2 is independently same or different drug molecule residue; a is 0 or 1; b is an integer of 2-12; c is an integer of 0-7; d is 0 or 1. The conjugate could improve drug load capacity, water solubility, stability and activity of the drug.

  提供一种水溶性聚合物-氨基酸寡肽-药物的共轭物，其化学式（I）如下，并提供包含该共轭物的制药组合物。在该共轭物中，P是水溶性聚合物；X是一个连接基团，连接基团连接P和A1；A1、A2和A3中的每一个独立地是相同或不同的氨基酸残基或氨基酸类似物残基；D1和D2中的每一个独立地是相同或不同的药物分子残基；a为0或1；b是2-12的整数；c是0-7的整数；d为0或1。该共轭物能够提高药物的载荷能力、水溶性、稳定性和活性。
• ——
  作者：

  DOI：——

  日期：——
• HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS
  申请人：Yu, Chongxi

  公开号：EP2370406A1

  公开（公告）日：2011-10-05
• US9700633B2
  申请人：——

  公开号：US9700633B2

  公开（公告）日：2017-07-11
• [EN] HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS<br/>[FR] COMPOSITIONS À PÉNÉTRATION ÉLEVÉE ET LEURS APPLICATIONS
  申请人：YU CHONGXI

  公开号：WO2010065936A1

  公开（公告）日：2010-06-10

  High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e. g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.